Loading…
Chinese medical-aesthetics company making injectable hyaluronic-acid dermal fillers (TradingView's specialty-chemicals label understates its health-care nature).
Chinese medical-aesthetics company making injectable hyaluronic-acid dermal fillers (TradingView's specialty-chemicals label understates its health-care nature).
Sells injectable fillers to clinics and hospitals, with each product needing approval from China's drug regulator as a medical device, so its approved range, not factory output, limits sales. Clinics, not patients, are the direct buyers, so doctors' preference matters.
In one line: A Chinese Allergan Aesthetics (dermal fillers)/Galderma.
Moat: narrow (regulatory licence, brand, IP / patents). Regulatory approval for injectable fillers is slow to obtain; IMEIK holds one of the broadest approved filler portfolios in China.
Headquarters: Beijing, China · Employees: 1,458
Size IMEIK Technology Development (300896.SZ) is a China Materials company (Chemicals: Specialty) with a market value of $3.92B, the 655th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥90.33 on 6 Nov 2026.
Performance Over six months the shares fell 21.5%, against -21.8% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue fell 7.3% over the last twelve months (peer median +13.9%); the operating margin is 44.6% (peer median 11.9%).
Valuation It trades at 23.3× forward earnings against a peer median of 15.9× (8th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.8 points above its cost of capital (11.1% WACC).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.33B | CN¥2.42B | CN¥3.01B | CN¥2.86B | CN¥1.93B |
| Revenue growth | — | -20% | +5% | +48% | — |
| Gross profit | CN¥2.16B | CN¥2.19B | CN¥2.80B | CN¥2.67B | CN¥1.81B |
| EBITDA | n/a | CN¥1.39B | CN¥2.20B | CN¥2.11B | CN¥1.40B |
| Net income | CN¥989M | CN¥1.29B | CN¥1.96B | CN¥1.86B | CN¥1.26B |
| Free cash flow | CN¥888M | CN¥1.22B | CN¥1.74B | CN¥1.92B | CN¥1.06B |
| Capital expenditure | CN¥191M | CN¥171M | CN¥239M | CN¥63.7M | CN¥156M |
| Total debt | CN¥31.9M | CN¥32.1M | CN¥45.0M | CN¥52.5M | CN¥59.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| IMEIK Technology Development 300896.SZ | $3.92B | -21% | -7% | 45% | 23.3× | 18.8% |
| Bloomage Biotechnology 688363.SS | $2.49B | -16% | -22% | 5% | 55.6× | 20.8% |
| AbbVie ABBV | $515B | +45% | +11% | 36% | 18.4× | -0.1% |
| Galderma GALD.SW | $54.8B | +17% | +16% | 19% | 48.1× | 18.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300896.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.1% | -5.5% | 11th highest of 21 |
| 6-month return | -21.5% | -21.8% | 10th highest of 20 |
| Distance from 52-week high | -46.4% | -39.2% | 7th lowest of 21 |
| Revenue growth (TTM) | -7.3% | +13.9% | lowest of 21 |
| Operating margin | 44.6% | 11.9% | highest of 21 |
| Forward P/E | 23.3× | 15.9× | 8th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 18.8% | 5.3% | 5th most demanding of 16 |
| Growth delivered (Del g) | +28.0% | +8.5% | 3rd highest of 16 |
| Hurdle (Req g minus delivered) | -9.1 pp | -5.1 pp | 7th least demanding of 16 |
| ROIC minus cost of capital | +3.8 pp | +0.6 pp | 7th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| IMEIK Technology Development 300896.SZ | China | $3.92B | -21% | -7% | 45% | 23.3× | 18.8% | +28.0% |
| Air Water 4088.T | Japan | $3.93B | +23% | +7% | 4% | 14.3× | 7.1% | +6.8% |
| Hangzhou Oxygen Plant 002430.SZ | China | $3.89B | -16% | +16% | 11% | 20.9× | 2.9% | +8.5% |
| Bluestar Adisseo 600299.SS | China | $3.97B | -35% | +15% | 13% | 11.8× | -8.6% | +7.7% |
| Pangang Group Vanadium & Titanium Resources 000629.SZ | China | $3.83B | -24% | +6% | 4% | 68.8× | 27.2% | -3.4% |
| Mitsubishi Gas Chemical 4182.T | Japan | $3.78B | -31% | +3% | 8% | 10.6× | n/a | n/a |
| Do-Fluoride New Materials 002407.SZ | China | $4.06B | -36% | +69% | 7% | 38.0× | 19.2% | +17.5% |
| Novoray 688300.SS | China | $3.76B | -9% | +23% | 26% | 52.7× | 47.6% | +22.6% |
| Ningbo Shanshan 600884.SS | China | $3.71B | -34% | +30% | 9% | 14.4× | 4.5% | +21.3% |
| Cabot CBT | United States | $3.67B | -17% | +1% | 14% | 10.9× | -3.2% | +1.9% |
| Cathay Biotech 688065.SS | China | $4.22B | -19% | +9% | 18% | 38.8× | n/a | n/a |
| NOF 4403.T | Japan | $3.60B | -22% | +13% | 17% | 13.5× | -6.1% | +8.4% |
| Jiangsu Nata Opto-electronic Material 300346.SZ | China | $4.29B | -22% | +15% | 16% | 62.1× | 35.6% | +34.2% |
| Clariant CLN.SW | Switzerland | $4.32B | +46% | -7% | 10% | 16.0× | -3.4% | +0.3% |
| Guangxi Huaxi Nonferrous Metal 600301.SS | China | $4.33B | -15% | +24% | 32% | 22.9× | 9.2% | +44.9% |
| Red Avenue New Materials 9607.HK | Hong Kong | $4.35B | n/a | +30% | 9% | 26.9× | n/a | n/a |
| GEM 002340.SZ | China | $4.43B | -36% | +2% | 7% | 15.7× | 4.2% | +24.4% |
| Far Eastern New Century 1402.TW | Taiwan | $4.49B | +8% | 0% | 6% | 11.8× | 5.3% | +4.2% |
| Guangzhou Guanggang Gases and Energy 688548.SS | China | $3.39B | -14% | +21% | 20% | 62.3× | n/a | n/a |
| Inner Mongolia Berun Chemical 000683.SZ | China | $3.36B | -32% | +11% | 13% | 13.8× | n/a | n/a |
| Zhejiang Sanmei Chemical Industry 603379.SS | China | $4.64B | -22% | +24% | 41% | 13.5× | 5.4% | +16.5% |